021-51111890
购物车（）
sales@molnova.cn
Cbz-NH-PEG1-CH2CH2COOH
CAS No. 1205751-19-4
Cbz-NH-PEG1-CH2CH2COOH ( —— )
产品货号. M26933 CAS No. 1205751-19-4
Cbz-NH-PEG1-CH2CH2COOH 是一种基于 PEG 的 PROTAC 连接体，可用于 PROTAC 的合成。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 50MG | ￥92 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Cbz-NH-PEG1-CH2CH2COOH
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Cbz-NH-PEG1-CH2CH2COOH 是一种基于 PEG 的 PROTAC 连接体，可用于 PROTAC 的合成。
-
产品描述Cbz-NH-PEG1-CH2CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.(In Vitro):PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
-
体外实验PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
-
体内实验——
-
同义词——
-
通路Others
-
靶点Other Targets
-
受体AMPAR
-
研究领域——
-
适应症——
化学信息
-
CAS Number1205751-19-4
-
分子量267.281
-
分子式C13H17NO5
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : 100 mg/mL (374.14 mM)
-
SMILESOC(=O)CCOCCNC(=O)OCc1ccccc1
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Koike M, et al. Blocking effect of 1-naphthyl acetyl spermine on Ca2+-permeable AMPA receptors in cultured rat hippocampal neurons. Neurosci Res. 1997 Sep;29(1):27-36.
产品手册
关联产品
-
TMPD dihydrochloride
TMPD diHClide 是酶促转化氧化还原的活性底物，也是血红素过氧化物酶还原的电子供体。
-
Peptide YY (canine, ...
Peptide YY (pig) 是一种长 36 个氨基酸的胃肠肽，可从猪十二指肠分离得到。Peptide YY (pig) 能够激活 Y2 receptor，以降低食欲和食物摄入量。Peptide YY (pig) 主要存在于胰腺内分泌细胞中，对肠动力和心血管系统都有影响。
-
Ciamexon
Ciamexon (Ciamexone) is a novel immunomodulator that has shown promising results in experimental models of autoimmune disease with little demonstrated cytotoxicity.Ciamexon can be used to study endocrine ophthalmopathies and diabetes mellitus, with slight improvement in ophthalmic disease following short-term administration.
